Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploring Lenvatinib Plus TACE Versus Sorafenib Plus TACE for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: Efficacy, Safety and Outcome Analysis

NCT04127396 is registered in ClinicalTrials.gov with Beijing Ditan Hospital as lead sponsor.

NCT NCT04127396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04127396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploring Lenvatinib Plus TACE Versus Sorafenib Plus TACE for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: Efficacy, Safety and Outcome Analysis
Lead sponsor
Beijing Ditan Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
September 1, 2019
Completion date
December 1, 2021
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular, portal vein tumor thrombus